These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 25558834)

  • 1. Use of three-compartment physiologically based pharmacokinetic modeling to predict hepatic blood levels of fluvoxamine relevant for drug-drug interactions.
    Iga K
    J Pharm Sci; 2015 Apr; 104(4):1478-91. PubMed ID: 25558834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simulation of Metabolic Drug-Drug Interactions Perpetrated by Fluvoxamine Using Hybridized Two-Compartment Hepatic Drug-Pool-Based Tube Modeling and Estimation of In Vivo Inhibition Constants.
    Iga K
    J Pharm Sci; 2015 Oct; 104(10):3565-77. PubMed ID: 26099559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance.
    Iga K
    J Pharm Sci; 2016 Mar; 105(3):1307-17. PubMed ID: 26886336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
    Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.
    DeVane CL; Gill HS
    J Clin Psychiatry; 1997; 58 Suppl 5():7-14. PubMed ID: 9184622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors.
    de Weger VA; Goel S; von Moos R; Schellens JHM; Mach N; Tan E; Anand S; Scott JW; Lassen U
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):73-80. PubMed ID: 29101463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects.
    Li Y; Liu L; Wang X; Zhang C; Reyes J; Hoffmann M; Palmisano M; Zhou S
    J Clin Pharmacol; 2018 Oct; 58(10):1295-1304. PubMed ID: 29762875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia.
    Chiu CC; Lane HY; Huang MC; Liu HC; Jann MW; Hon YY; Chang WH; Lu ML
    J Clin Pharmacol; 2004 Dec; 44(12):1385-90. PubMed ID: 15545309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction.
    Granfors MT; Backman JT; Neuvonen M; Ahonen J; Neuvonen PJ
    Clin Pharmacol Ther; 2004 Apr; 75(4):331-41. PubMed ID: 15060511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of Two-Compartment Model-Assisted and Static Overall Inhibitory-Activity Method for Prediction of Drug-Drug Interaction.
    Iga K; Kiriyama A
    Biol Pharm Bull; 2017 Dec; 40(12):2024-2037. PubMed ID: 28993551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist.
    Ogilvie BW; Torres R; Dressman MA; Kramer WG; Baroldi P
    J Clin Pharmacol; 2015 Sep; 55(9):1004-11. PubMed ID: 25851638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone.
    Chen Y; Mao J; Hop CE
    Drug Metab Dispos; 2015 Feb; 43(2):182-9. PubMed ID: 25324279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effects of Fluvoxamine on the Steady-State Plasma Concentrations of Escitalopram and Desmethylescitalopram in Depressed Japanese Patients.
    Yasui-Furukori N; Tsuchimine S; Kubo K; Ishioka M; Nakamura K; Inoue Y
    Ther Drug Monit; 2016 Aug; 38(4):483-6. PubMed ID: 27002781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects.
    de Vries MH; Raghoebar M; Mathlener IS; van Harten J
    Ther Drug Monit; 1992 Dec; 14(6):493-8. PubMed ID: 1485372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood clozapine levels elevated by fluvoxamine: potential for side effects and lower clozapine dosage.
    Armstrong SC; Stephans JR
    J Clin Psychiatry; 1997 Nov; 58(11):499. PubMed ID: 9413421
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior.
    Geldof M; Freijer J; van Beijsterveldt L; Vermote PC; Megens AA; Danhof M
    Eur J Pharm Sci; 2007 Nov; 32(3):200-8. PubMed ID: 17825539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans.
    Becquemont L; Ragueneau I; Le Bot MA; Riche C; Funck-Brentano C; Jaillon P
    Clin Pharmacol Ther; 1997 Jun; 61(6):619-27. PubMed ID: 9209244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic modeling of non-linear brain distribution of fluvoxamine in the rat.
    Geldof M; Freijer J; van Beijsterveldt L; Danhof M
    Pharm Res; 2008 Apr; 25(4):792-804. PubMed ID: 17710515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of human brain pharmacokinetics using a two-compartment model.
    Strauss WL; Layton ME; Dager SR
    Biol Psychiatry; 1999 May; 45(10):1384-8. PubMed ID: 10349045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation.
    Lu C; Suri A; Shyu WC; Prakash S
    Biopharm Drug Dispos; 2014 Dec; 35(9):543-52. PubMed ID: 25264242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.